

Anti-Cancer Drugs 2008

Author Index to Volume I9

- Aarnink A. *See* Labussière M, 991
 Adamo V. *See* Caponigro F, 739
 Adin C. *See* Barabas K, 495
 Adrover E. *See* Barnadas A, 339
 Aglietta M. *See* Cavalloni G, 689
 Ahn K-S. *See* Park J, 777
 Ahuja N. *See* Myc A, 143
 Aisner J. *See* Saraiya B, 411
 Alessandrini P. *See* Rossi D, 733
 Alexandre J. *See* Cacheux W, 295
 Allen SL. *See* Calabro A, 705
 Alm K. *See* Myhre L, 359
 Almhanna K *et al.* Subcutaneous implantable venous access device erosion through the skin in patients treated with anti-vascular endothelial growth factor therapy: a case series, 217
 Amadori D. *See* Arienti C, 983
 Amato RJ *et al.* Interferon- α in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial, 527
 Ammannati F. *See* Scoccianti S, 613
 Anderluh G. *See* Soletti RC, 517
 Anizon F. *See* Rossignol E, 789
 Antoniou D. *See* Giannakopoulos S, 325
 Anwer K. *See* Sonabend AM, 133
 Aogi K. *See* Tokudome N, 753
 Aoki H. *See* Kaira K, 289
 Appella DH. *See* Norton JT, 23
 Aprile G *et al.* From the podium to the patient: bringing the 2008 ASCO meeting to the clinic, 941; *also see* Puglisi F, 221
 Archer L. *See* Barabas K, 495
 Arienti C *et al.* Activity of lipoplatin in tumor and in normal cells *in vitro*, 983
 Asaishi K. *See* Nishimura R, 911
 Auriola S. *See* Mönkkönen H, 391
 Avery-Kiejda KA. *See* Zhu B-k, 189
 Avram MJ. *See* Norton JT, 23
 Azak A *et al.* Cerebrovascular accident during cisplatin-based combination chemotherapy of testicular germ cell tumor: an unusual case report, 97
 Azim HA and Mok T. Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life, 645
 Azuma M. *See* Ishido K, 921
 Bae E-K. *See* Park J, 777
 Bagarry-Liegey D. *See* Dupuis C, 267
 Baker JR. *See* Myc A, 143
 Baldelli AM. *See* Rossi D, 733
 Baldwin J. *See* Camidge DR, 77
 Bao H *et al.* Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients, 317
 Barabas K *et al.* Hyperbilirubinemia's protective effect against cisplatin nephrotoxicity in the Gunn rat, 495
 Barberi-Heyob M. *See* Labussière M, 991
 Barnadas A *et al.* Neoadjuvant endocrine therapy for breast cancer: past, present and future, 339
 Bartelink H. *See* Zerp SF, 65
 Basche M. *See* Camidge DR, 77
 Ba-Ssalamah A. *See* Hejna M, 535
 Battistelli S. *See* Petrioli P, 91
 Baylis C. *See* Barabas K, 495
 Beagle KL. *See* Hall PD, 1007
 Beijnen JH. *See* Brouwers EEM, 621
 Belvedere O. *See* Aprile G, 941
 Bernier-Chastagner V. *See* Labussière M, 991
 Bernstein-Molho R. *See* Merimsky O, 1019
 Bian X-W. *See* Zhao J, 713
 Biti G. *See* Scoccianti S, 613
 Bolaños-Meade J. *See* Vilella L, 917
 Borbolla-Escoboza JR. *See* Vilella L, 917
 Bordi L. *See* Scoccianti S, 613
 Borges HL. *See* Soletti RC, 517
 Borghesi S. *See* Scoccianti S, 613
 Bouabdallah K. *See* Validire P, 309
 Bouma-ter Steege JCA. *See* Weidenaar AC, 45
 Bourougaa K. *See* Hrstka R, 369
 Boven E. *See* Staffhorst RWHM, 721
 Bratta M. *See* Recchia F, 201
 Brem H. *See* Sonabend AM, 133
 Brice P. *See* Validire P, 309
 Britten CD. *See* Camidge DR, 77
 Brodowicz T. *See* Hejna M, 535
 Brouwers EEM *et al.* The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography-inductively coupled plasma mass spectrometry, 621
 Bruni P. *See* Orciani M, 599
 Budde M. *See* Zerp SF, 65
 Budman DR. *See* Calabro A, 705
 Caballero R. *See* Vilella L, 917
 Cacheux W *et al.* An original administration of ifosfamide given once every other week: a clinical and pharmacological study, 295
 Cai J-b. *See* Tong Q-S, 573
 Cai Y. *See* Yang X, 421
 Calabro A *et al.* In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia, 705
 Calvo L. *See* Barnadas A, 339
 Camidge DR *et al.* A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors, 77
 Candeias MM. *See* Hrstka R, 369
 Candeloro G. *See* Recchia F, 201
 Cao J. *See* Li J, 745
 Caponigro F *et al.* A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck, 739
 Carde P. *See* Validire P, 309
 Carloni S. *See* Arienti C, 983
 Carper SW. *See* Yeruva L, 766
 Casadei V. *See* Rossi D, 733
 Catalano G. *See* Rossi D, 733
 Catalano V. *See* Rossi D, 733
 Cavaletti G. *See* Orciani M, 599
 Cavalloni G *et al.* Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab, 689
 Ceccolini M. *See* Rossi D, 733
 Chan LS *et al.* Alterations in vascular architecture and permeability following OXi4503 treatment, 17
 Chang J-Y. *See* Kao Y-H, 151
 Chang Y-F. *See* Hwang W-S, 283
 Chao T-Y. *See* Hwang W-S, 283
 Chaoui D. *See* Validire P, 309
 Chastagner P. *See* Labussière M, 991
 Chen J-S. *See* Chu Z, 275
 Chen LH. *See* Zhu B-k, 189
 Chen M-H *et al.* Galloyl cyclic-imide derivative CH1104i inhibits tumor invasion through suppressing matrix metalloproteinase activity, 957
 Chen P-M. *See* Chu Z, 275; *also see* Hwang W-S, 283
 Chen W. *See* Zhao J, 713
 Chen Y-J *et al.* Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells, 55
 Cheng Y-N. *See* Chen M-H, 957
 Chiou T-J. *See* Hwang W-S, 283
 Chitlimala SK. *See* Kao Y-H, 151
 Chiu C-F. *See* Hwang W-S, 283
 Cho EK. *See* Park SH, 303
 Cho JY. *See* Lim JY, 631
 Choi E-J. *See* Lee S, 503
 Choi H-r. *See* Lee S, 503
 Choi J-Y. *See* Lee S, 503
 Christophi C. *See* Chan L, 17
 Chu Z *et al.* Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients, 275
 Chuang S-E. *See* Kao Y-H, 151
 Chung C-Y. *See* Hwang W-S, 283
 Chung M. *See* Park SH, 303
 Chunhu Z *et al.* Antiproliferative and apoptotic effects of paeonol on human hepatocellular carcinoma cells, 401
 Ciccolini J. *See* Dupuis C, 267
 Civitelli S. *See* Petrioli P, 91
 Codecà C. *See* Ferrari D, 837
 Collazo C. *See* Saraiya B, 411
 Conus NM. *See* Dawson S-J, 547
 Couvreur P. *See* Reddy LH, 999
 Creaven PJ. *See* Ramnath N, 749

- Crocker B. *See* Barabas K, 495
Cui J. *See* Tang C, 697
Cui J-r. *See* Pang L-p, 167
Cui JR. *See* Zhang N, 593
Cui S-X. *See* Chen M-H, 957
Cui W *et al.* In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice, 891
Cui Y *et al.* Nordinhydroguaiaretic acid restores expression of silenced E-cadherin gene in human breast cancer cell lines and xenografts, 487
da Cunha Vasconcelos F. *See* Kwee JK, 975
Dadashzadeh S *et al.* 9-Nitrocamptothecin polymeric nanoparticles: cytotoxicity and pharmacokinetic studies of lactone and total forms of drug in rats, 805
Darstein C. *See* Camidge DR, 77
Davidson J. *See* Almhanna K, 217
Dawson S-J *et al.* Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma, 547
de Bont ESJM. *See* Weidenaar AC, 45
de Cremoux P. *See* Decaudin D, 761
de Faria GP. *See* Soletti RC, 517
de Jong D. *See* Zerp SF, 65
de Jonge HJM. *See* Weidenaar AC, 45
de Kroon AIPM. *See* Staffhorst RWHM, 721
de la Haba J. *See* Barnadas A, 339
de Wilt JHW. *See* Mearadji A, 607
Debiton E. *See* Rossignol E, 789
Decaudin D *et al.* Treatment of mucosa-associated lymphoid tissue-type ocular adnexal lymphoma, 673; *also* Variable association between *Chlamydia psittaci* infection and ocular adnexal lymphomas: methodological biases or true geographical variations?, 761; *also see* Validire P, 309
den Bakker MA. *See* Mearadji A, 607
Dendale R. *See* Decaudin D, 673; *also* Decaudin D, 761
Derakhshandeh K. *See* Dadashzadeh S, 805
Deren T. *See* Azak A, 97
Desai NP *et al.* Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status, 899
Desmaele D. *See* Reddy LH, 999
Detti B. *See* Scoccianti S, 613
Deubzer HE. *See* Wegener D, 849
Devaraja R. *See* Ekambara G, 885
Deville J-L. *See* Dupuis C, 267
Di Maria G. *See* Ferrari D, 837
Di Primio R. *See* Orciani M, 599
Di Wang X. *See* Kang G-S, 859
Diviné M. *See* Validire P, 309
Doglioni C. *See* Decaudin D, 761
Doi T. *See* Nishimura R, 911
Dolcet X. *See* Llobet D, 115
Dolcetti R. *See* Decaudin D, 761
Dong J-H. *See* Tong Q-S, 573
dos Santos Ferreira AC. *See* Kwee JK, 975
Douce TB. *See* Myc A, 143
Douwes J. *See* Weidenaar AC, 45
Dowlati A *et al.* SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2, 9
Dubernet C. *See* Reddy LH, 999
Duffau B. *See* Cacheux W, 295
Duffaud F. *See* Dupuis C, 267
Dupuis C *et al.* High-dose methotrexate in adults with osteosarcoma: population pharmacokinetics study and validation of a new limited sampling strategy, 267
Durand A. *See* Dupuis C, 267
Dutta J. *See* Saraiya B, 411
Eggermont AMM. *See* Mearadji A, 607
Ekambara G *et al.* Impact of naringenin on glycoprotein levels in N-methyl-N'-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats, 885
Elegbede JA. *See* Yeruva L, 766
Encinas M. *See* Llobet D, 115
Eritja N. *See* Llobet D, 115
Erkelens CAM. *See* Staffhorst RWHM, 721
Escande M-C. *See* Decaudin D, 761
Escanyé J-M. *See* Labussière M, 991
Estevez LG. *See* Barnadas A, 339
Evans A. *See* Mönkkönen H, 391
Fabbro D. *See* Rossignol E, 789
Fähræus R. *See* Hrstka R, 369
Faller DV. *See* Rankin AM, 329
Fanciullino R. *See* Dupuis C, 267
Faoro L *et al.* Protein kinase C beta in malignant pleural mesothelioma, 841
Fareau GG *et al.* Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies, 637
Farese J. *See* Barabas K, 495
Fasola G. *See* Puglisi F, 221
Favre R. *See* Dupuis C, 267
Fazio N. *See* Ferrari D, 837
Fedeli SL. *See* Rossi D, 733
Fermé C. *See* Validire P, 309
Ferrari D *et al.* Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy, 837
Ferreira H. *See* Reddy LH, 999
Ferreri AJM. *See* Decaudin D, 761
Fettner S. *See* Ling J, 209
Fewell JG. *See* Sonabend AM, 133
Fiaschi AI. *See* Petrioli P, 91
Fidler V. *See* Weidenaar AC, 45
Figg WD. *See* Chu Z, 275
Finn RS. *See* Camidge DR, 77
Fino V. *See* Orciani M, 599
Fiore J. *See* Ferrari D, 837
Fischer SM. *See* Riedel SB, 175
Fitoussi O. *See* Validire P, 309
Foa P. *See* Ferrari D, 837
Franchin G. *See* Caponigro F, 739
Francini E. *See* Petrioli P, 91
Francini G. *See* Petrioli P, 91
Frankel AE. *See* Hall PD, 1007
Frisk P. *See* Molin Y, 812
Fujiwara Y *et al.* Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine, 431
Fumagalli L. *See* Recchia F, 201
Futawata N. *See* Ishido K, 921
Gabarre J. *See* Validire P, 309
Gabilan NH. *See* Soletti RC, 517
Gail Eckhardt S. *See* Camidge DR, 77
Gammaitoni L. *See* Cavalloni G, 689
García M. *See* Vilella L, 917
Gardner ER. *See* Chu Z, 275
Garrett-Mayer E. *See* Hall PD, 1007
Ge Z. *See* Zhang N, 593
Geisert EE. *See* Kang G-S, 859
Gemba K. *See* Fujiwara Y, 431
Germann N. *See* Cacheux W, 295
Gharibo M. *See* Saraiya B, 411
Ghosh S. *See* Norton JT, 23
Giannakopoulos S *et al.* Severe bladder contracture leading to cystectomy after intravesical mitoxantrone chemotherapy, 325
Gil M. *See* Barnadas A, 339
Gilbert JL *et al.* Comparative evaluation of viral, nonviral and physical methods of gene delivery to normal and transformed lung epithelial cells, 783
Giordani P. *See* Rossi D, 733
Glisson BS. *See* Saigal B, 465
Goldwasser F. *See* Cacheux W, 295
Gore L. *See* Camidge DR, 77
Gottlieb RH. *See* Ramnath N, 749
Gounder M. *See* Saraiya B, 411
Gourmel B. *See* Cacheux W, 295
Gradishar WJ. *See* Desai NP, 899
Graziano F. *See* Rossi D, 733
Gubernator J. *See* Sermsappasak P, 729
Guilin X. *See* Chunhu Z, 401
Guo W. *See* Pang L-p, 167; *also* Zhang N, 593
Gupta V and Singh SM. Sex dimorphism in antitumor response of chemotherapeutic drug cisplatin in a murine host-bearing a T-cell lymphoma, 583
Hählen K. *See* Weidenaar AC, 45
Hall PD *et al.* Reducing anti-DT IgG concentrations to improve the efficacy of a diphtheria fusion protein, 1007
Halmos B. *See* Dowlati A, 9
Halmos G. *See* Szepeshazi K, 349
Hamakawa H. *See* Harada K, 85
Hamelers IHL. *See* Staffhorst RWHM, 721
Han Y. *See* Sonabend AM, 133
Hang X. *See* Liu C, 825; *also* Zhong H, 1013
Hao YZ. *See* Zhang LJ, 159
Harada K *et al.* Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma, 85
Harbeck N. *See* Stemmler H-J, 832
Hatake K. *See* Tokudome N, 753
Hegardt C. *See* Myhre L, 359; *also* Holst CM, 871
Heinemann V. *See* Stemmler H-J, 832
Hejna M *et al.* Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001, 535
Hemsen A. *See* Strauss H-G, 541
Hernandez-McClain J. *See* Amato RJ, 527
Herrmann KA. *See* Stemmler H-J, 832
Hersey P. *See* Zhang LJ, 159; *also* Zhu B-k, 189
Hicks RJ. *See* Dawson S-J, 547
Higuchi K. *See* Ishido K, 921
Hildmann C. *See* Wegener D, 849
Hisada T. *See* Kaira K, 289
Hofmann R. *See* Schrader AJ, 235
Holden SN. *See* Camidge DR, 77
Holen I. *See* Mönkkönen H, 391

- Holst CM *et al.* Molecular mechanisms underlying N^1 , N^{11} -diethylnorspermine-induced apoptosis in a human breast cancer cell line, 871
- Hong J. *See* Park SH, 303
- Hong S-J. *See* Lee S, 503
- Hong X. *See* Yang X, 421
- Hotta K. *See* Fujiwara Y, 431
- Hrstka R *et al.* The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin, 369
- Hrynyk R. *See* Sermsappasuk P, 729
- Hsieh H-P. *See* Kao Y-H, 151
- Hu CS. *See* Zhang LJ, 159
- Hu J. *See* Cui Y, 487
- Hu K-Q. *See* Cui W, 891
- Hu SX. *See* Cui W, 891
- Hu X. *See* Yang X, 421
- Hu Z-Y. *See* Sun J, 967
- Huang S. *See* Norton JT, 23
- Huang W. *See* Pang L-p, 167; *also* Zhang N, 593
- Huitema ADR. *See* Brouwers EEM, 621
- Husain AN. *See* Faoro L, 841
- Hwang LY. *See* Desai NP, 899
- Hwang W-S *et al.* Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer, 283
- Hyodo I. *See* Koizumi W, 819
- Iannalfi A. *See* Scoccianti S, 613
- Iizuka D *et al.* Purvalanol A induces apoptosis and downregulation of antiapoptotic proteins through abrogation of phosphorylation of JAK2/STAT3 and RNA polymerase II, 565
- Ilbäck N-G. *See* Molin Y, 812
- Iliadis A. *See* Dupuis C, 267
- Inaba M. *See* Nishimura R, 911
- Inanami O. *See* Iizuka D, 565
- Ishido K *et al.* A patient with stage IV type 4 advanced gastric cancer who had a complete pathological response to short-term treatment with S-1 alone, 921
- Ishizuka T. *See* Kaira K, 289
- Ito Y. *See* Tokudome N, 753
- Iwata H. *See* Tokudome N, 753
- Iyer RV. *See* Ramnath N, 749
- Jac J. *See* Amato RJ, 527
- Jacobson PA. *See* Kirstein MN, 37
- Jafri M and Protheroe A. Cisplatin-associated thrombosis, 927
- Jauhainen M. *See* Mönkkönen H, 391
- Jeung H-C. *See* Lim JY, 631
- Jiang CC. *See* Zhu B-k, 189
- Jiang G-S. *See* Tong Q-S, 573
- Jiang W-Q. *See* Sun J, 967
- Johnson FM. *See* Saigal B, 465
- Jönsson G. *See* Myhre L, 359; *also* Holst CM, 871
- Jun C-D. *See* Lee S, 503
- Kaira K *et al.* Phase I trial of oral S-1 plus gemcitabine in elderly patients with non-small cell lung cancer, 289
- Kalaitzis C. *See* Giannakopoulos S, 325
- Kamps WA. *See* Weidenaar AC, 45
- Kang A. *See* Cui Y, 487
- Kang G-S *et al.* Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma, 859
- Kang H. *See* Park S-k, 381
- Kao Y-H *et al.* A novel peroxisome proliferator-activated receptor α/γ agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells, 151
- Karbe I. *See* Strauss H-G, 541
- Katada C. *See* Ishido K, 921
- Katirtzoglu NA. *See* Saif MW, 447
- Kawamura A. *See* Norton JT, 23
- Kawata T. *See* Kaira K, 289
- Kern JA. *See* Dowlati A, 9
- Khushalani NI. *See* Ramnath N, 749
- Kim BK. *See* Park J, 777
- Kim B-S. *See* Park J, 777
- Kim J-A. *See* Lee S, 503
- Kim O-j. *See* Lee S, 503
- Kim YS. *See* Park SH, 303
- Kimura M. *See* Nishimura R, 911
- Kindler HL. *See* Faoro L, 841
- Kirichenko OV. *See* Kang G-S, 859
- Kirstein MN *et al.* Exposure-response relationships for oxaliplatin-treated colon cancer cells, 37
- Kiura K. *See* Fujiwara Y, 431
- Kline K. *See* Riedel SB, 175
- Kluge A. *See* Dowlati A, 9
- Klumb CE. *See* Kwee JK, 975
- Koizumi W *et al.* Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase, 819; *also* *see* Ishido K, 921
- Kojima H. *See* Koizumi W, 819
- Koolwijk P. *See* Zerp SF, 65
- Kotlyar A. *See* Myc A, 143
- Kukowska-Latallo J. *See* Myc A, 143
- Kuo C-C. *See* Kao Y-H, 151
- Kuo C-D. *See* Chen Y-J, 55
- Kuokkanen J. *See* Mönkkönen H, 391
- Kuwabara M. *See* Iizuka D, 565
- Kvardova V. *See* Hrsta R, 369
- Kwee JK *et al.* Modulation of reactive oxygen species by antioxidants in chronic myeloid leukemia cells enhances imatinib sensitivity through survivin downregulation, 975
- Kwon C-H. *See* Park S-k, 381
- Labussière M *et al.* Interest of liposomal doxorubicin as a radiosensitizer in malignant glioma xenografts, 991
- Lacko AG. *See* McConathy WJ, 183
- Laessig D. *See* Stemmler H-J, 832
- Larsson S. *See* Myhre L, 359
- Lautenschläger C. *See* Strauss H-G, 541
- Lee DK. *See* Lim JY, 631
- Lee JH. *See* Park SH, 303
- Lee S *et al.* Gene induction by glycyrol to apoptosis through endonuclease G in tumor cells and prediction of oncogene function by microarray analysis, 503
- Lee S-H. *See* Lee S, 503
- Lee SJ. *See* Lim JY, 631
- Lee WK. *See* Park SH, 303
- Lee Y-Y. *See* Park J, 777
- Lefley DV. *See* Mönkkönen H, 391
- Lei Y. *See* Lu C-X, 931
- Leone F. *See* Cavalloni G, 689
- Leong S. *See* Camidge DR, 77
- Leonulli BG. *See* Scoccianti S, 613
- Lesniak MS. *See* Sonabend AM, 133
- Li A. *See* Zhou H-J, 247
- Li J *et al.* Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer, 745; *also* *see* Yang X, 421
- Li M. *See* Zhang N, 593; *also* Tang C, 697
- Li Q-B. *See* Chen M-H, 957
- Li R-t. *See* Pang L-p, 167
- Li RT. *See* Zhang N, 593
- Li Y-M. *See* Zhao J, 713
- Li Z-M. *See* Sun J, 967
- Liao H-F. *See* Chen Y-J, 55
- Liau C-T. *See* Chu Z, 275
- Lim JY *et al.* Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma, 631
- Lim W-B. *See* Lee S, 503
- Lin S-F. *See* Hwang W-S, 283
- Lin W-H. *See* Kao Y-H, 151
- Lin X-B. *See* Sun J, 967
- Lin Y. *See* Saraiya B, 411
- Lin Y-C. *See* Chu Z, 275
- Ling J *et al.* Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals, 209
- Liu C *et al.* Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer, 825
- Liu J. *See* Tang C, 697
- Liu L. *See* Cui Y, 487
- Liu Y. *See* Tong Q-S, 573; *also* Li J, 745
- Llobet D *et al.* Antioxidants block proteasome inhibitor function in endometrial carcinoma cells, 115
- Llombart A. *See* Barnadas A, 339
- Llombart-Cussac A. *See* Llobet D, 115
- Loganathan S. *See* Faoro L, 841
- Lopez A. *See* Fareau GG, 637
- López-Brea M. *See* Rivera F, 99
- Lorenzi M. *See* Petrioli P, 91
- Lu C. *See* Cui Y, 487
- Lu C-X *et al.* Agents from amphibians with anticancer properties, 931
- Lu F. *See* Li J, 745
- Luciani A. *See* Ferrari D, 837
- Lukyanov Y. *See* Newcomb EW, 553
- Lum BL. *See* Ling J, 209
- Lumbroso-Le Rouic L. *See* Decaudin D, 673
- Luong L. *See* Norton JT, 23
- Luque DG. *See* Kwee JK, 975
- Ma S. *See* Zhong H, 1013
- Ma X. *See* Cui Y, 487
- Maggioni M. *See* Ferrari D, 837
- Maia RC. *See* Kwee JK, 975
- Malcontenti-Wilson C. *See* Chan LS, 17
- Mangianti S. *See* Arienti C, 983
- Mari E. *See* Caponigro F, 739
- Marker PH. *See* Kirstein MN, 37
- Marsili S. *See* Petrioli P, 91
- Marti RM. *See* Llobet D, 115
- Martinelli F. *See* Scoccianti S, 613
- Matar MM. *See* Sonabend AM, 133
- Matias-Guiu X. *See* Llobet D, 115
- Mattioli-Belmonte M. *See* Orciani M, 599
- McArthur G. *See* Dawson S-J, 547
- McCabe M. *See* Gilbert JL, 783

- McConathy WJ *et al.* Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel, 183
- Mearadji A *et al.* Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis, 607
- Meattini I. *See* Scoccianti S, 613
- Meeuwse-de Boer T. *See* Weidenaar AC, 45
- Meiqun C. *See* Chunhu Z, 401
- Mengele K. *See* Stemmler H-J, 832
- Mercier C. *See* Dupuis C, 267
- Merimsky O *et al.* Targeting the mammalian target of rapamycin in myxoid chondrosarcoma, 1019
- Migliardi G. *See* Cavalloni G, 689
- Milano A. *See* Caponigro F, 739
- Milde T. *See* Wegener D, 849
- Miller DD. *See* Kang G-S, 859
- Milner R. *See* Barabas K, 495
- Modi R. *See* Faoro L, 841
- Mohler ML. *See* Kang G-S, 859
- Mok T. *See* Azim HA, 645
- Molin Y *et al.* Sequential effects of daily arsenic trioxide treatment on essential and nonessential trace elements in tissues in mice, 812
- Monjanel-Mouterde S. *See* Dupuis C, 267
- Mönkkönen H *et al.* Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth, 391
- Mönkkönen J. *See* Mönkkönen H, 391
- Mooberry L. *See* McConathy WJ, 183
- Moore HCF. *See* Almhanna K, 217
- Moore MM. *See* Kirstein MN, 37
- Moreau P. *See* Rossignol E, 789
- Mori M. *See* Kaira K, 289
- Morrice B. *See* Caponigro F, 739
- Mouelhi SL. *See* Reddy LH, 999
- Moura-Neto V. *See* Soletti RC, 517
- Mun HS. *See* Lim JY, 631
- Muralidharan V. *See* Chan L, 17
- Musib L. *See* Camidge DR, 77
- Muthuvel R. *See* Ekambaram G, 885
- Myc A *et al.* Preclinical antitumor efficacy evaluation of dendrimer-based methotrexate conjugates, 143
- Myhre L *et al.* Different cell cycle kinetic effects of N^1,N^{11} -diethylnorspermine-induced polyamine depletion in four human breast cancer cell lines, 359
- Nagahata S. *See* Harada K, 85
- Nagayama M. *See* Harada K, 85
- Nair MP. *See* McConathy WJ, 183
- Nam E. *See* Park SH, 303
- Nan K-J. *See* Lu C-X, 931
- Nazar A. *See* Saraiya B, 411
- Necozione S. *See* Recchia F, 201
- Nethery D. *See* Dowlati A, 9
- Newcomb EW *et al.* Noscipine induces apoptosis in human glioma cells by an apoptosis-inducing factor-dependent pathway, 553
- Ng CS. *See* Osai WE, 427
- Nicoletti S. *See* Arienti C, 983
- Nishimura R *et al.* Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial, 911
- Norton JT *et al.* Synthesis and anticancer activities of 6-amino amonafide derivatives, 23
- O'Brien MER. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer, 1
- O'Brien T. *See* Gilbert JL, 783
- O'Bryant CL. *See* Camidge DR, 77
- O'Dea S. *See* Gilbert JL, 783
- Oehme I. *See* Wegener D, 849
- Ogura A. *See* Iizuka D, 565
- Oh H-K. *See* Lee S, 503
- Oh H-M. *See* Lee S, 503
- Okamoto Y. *See* Nishimura R, 911
- Okayasu I. *See* Koizumi W, 819
- Öksüzöglü B. *See* Azak A, 97
- Okuyama N. *See* Nishimura R, 911
- Oldani S. *See* Ferrari D, 837
- Omori M. *See* Fujiwara Y, 431
- Öneç BM. *See* Azak A, 97
- Orciani M *et al.* Exploiting CD38-mediated endocytosis for immunoliposome internalization, 599
- Oredsson SM. *See* Myhre L, 359; *also* Holst CM, 871
- Orr WE. *See* Kang G-S, 859
- Osai WE *et al.* Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma, 427
- Osaki T. *See* Harada K, 85
- Ou Z. *See* Yang X, 421
- Pacquement H. *See* Validire P, 309
- Pagliaro LC. *See* Osai WE, 427
- Paik YH. *See* Lim JY, 631
- Palaga T. *See* Suwanjuee S, 477
- Pan W-Y. *See* Kao Y-H, 151
- Pang L-p *et al.* SLXM-2, a derivative of cyclophosphamide: mechanism of growth inhibition on hepatocarcinoma 22 cells, 167
- Pantazis T. *See* Giannakopoulos S, 325
- Paranjape S. *See* McConathy WJ, 183
- Park J *et al.* Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells, 777; *also see* Park SH, 303
- Park SH *et al.* Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study, 303
- Park S-k *et al.* Caspase-dependent cell death mediates potent cytotoxicity of sulfide derivatives of 9-anilinoacridine, 381
- Park Y-N. *See* Lee S, 503
- Pascucci A. *See* Petrioli P, 91
- Patil R. *See* Kang G-S, 859
- Patris E. *See* Giannakopoulos S, 325
- Pelley RJ. *See* Almhanna K, 217
- Peng F. *See* Zhang H, 125
- Pepe S. *See* Caponigro F, 739
- Persing M. *See* Strauss H-G, 541
- Peters E. *See* Zerp SF, 65
- Peters GJ. *See* Staffhorst RWHM, 721
- Petrioli P *et al.* Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors, 91
- Piacibello W. *See* Cavalloni G, 689
- Pignochino Y. *See* Cavalloni G, 689
- Pinel S. *See* Labussière M, 991
- Plénat F. *See* Labussière M, 991
- Pluschnig U. *See* Hejna M, 535
- Ponzoni M. *See* Decaudin D, 761
- Pourroy B. *See* Dupuis C, 267
- Powell DJ. *See* Hrstka R, 369
- Protheroe A. *See* Jafri M, 927
- Prudhomme M. *See* Rossignol E, 789
- Puglisi F *et al.* Hot topics and landmark studies from the 43rd annual meeting of the American Society of Clinical Oncology, 221; *also see* Aprile G, 941
- Purcell J. *See* Gilbert JL, 783
- Püspök A. *See* Hejna M, 535
- Qiu T. *See* Bao H, 317
- Qu X-J. *See* Chen M-H, 957
- Rabillon F. *See* Cacheux W, 295
- Raderer M. *See* Hejna M, 535
- Rajendran P. *See* Ekambaram G, 885
- Rajkumar T and Yamuna M. Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line, 257
- Rakhit A. *See* Ling J, 209
- Raleigh JM. *See* Dawson S-J, 547
- Ramnath N *et al.* Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study, 749
- Rankin AM *et al.* Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity, 329
- Ratta M. *See* Arienti C, 983
- Ravaoli A. *See* Arienti C, 983
- Rea S. *See* Recchia F, 201
- Recchia F *et al.* Multicenter phase II study of chemioimmunotherapy in the treatment of metastatic melanoma, 201
- Reddy LH *et al.* Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms, 999
- Riedel SB *et al.* Vitamin E analog, α -tocopherol ether-linked acetic acid analog, alone and in combination with celecoxib, reduces multiplicity of ultraviolet-induced skin cancers in mice, 175
- Riek M. *See* Ling J, 209
- Rischin D. *See* Dawson S-J, 547
- Risio M. *See* Cavalloni G, 689
- Rivera F *et al.* Cetuximab, its clinical use and future perspectives, 99
- Rocha-Lima CM. New directions in the management of advanced pancreatic cancer: a review, 435
- Roforth MM and Tan C. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells, 681
- Romano C. *See* Caponigro F, 739
- Root SA. *See* Kirstein MN, 37
- Rossi D *et al.* Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in

- operable and locally advanced breast cancer, 733
- Rossignol E *et al.* In-vitro antiproliferative activities and kinase inhibitory potencies of meridianin derivatives, 789
- Roubalova E. *See* Hrstka R, 369
- Rouic LL-L. *See* Decaudin D, 761
- Rousseau B. *See* Reddy LH, 999
- Roviello F. *See* Petrioli P, 91
- Rubin EH. *See* Saraiya B, 411
- Ruiter GA. *See* Zerp SF, 65
- Rustum YM. *See* Ramnath N, 749
- Ryoke K. *See* Harada K, 85
- Saegusa M. *See* Ishido K, 921
- Saeki T. *See* Tokudome N, 753
- Sagi-Eisenberg R. *See* Merimsky O, 1019
- Saif MW *et al.* Capecitabine: an overview of the side effects and their management, 447
- Saigal B *et al.* Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma, 465
- Saigenji K. *See* Ishido K, 921
- Sakamoto J. *See* Koizumi W, 819
- Sakthisekaran D. *See* Ekambaram G, 885
- Saleem A. *See* Saraiya B, 411
- Salgia R. *See* Faoro L, 841
- Salhi R. *See* Validire P, 309
- Sánchez-Rovira P. *See* Barnadas A, 339
- Sanders BG. *See* Riedel SB, 175
- Sano M. *See* Tokudome N, 753
- Saraiya B *et al.* Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia, 411
- Sardaro A. *See* Scoccianti S, 613
- Sarotto I. *See* Cavalloni G, 689
- Sasaki T. *See* Ishido K, 921
- Sato M. *See* Harada K, 85
- Sato Y. *See* Tokudome N, 753
- Schaar D. *See* Saraiya B, 411
- Schaffer P. *See* Stemmler H-J, 832
- Schally AV. *See* Szepeshazi K, 349
- Schellens JHM. *See* Brouwers EEM, 621
- Schmidinger M. *See* Hejna M, 535
- Schmitt M. *See* Stemmler H-J, 832
- Schnee T. *See* Newcomb EW, 553
- Schoenenberger JA. *See* Llobet D, 115
- Schrader AJ and Hofmann R. Metastatic renal cell carcinoma: recent advances and current therapeutic options, 235
- Schuller HM. Neurotransmission and cancer: implications for prevention and therapy, 655
- Schwarz JK. *See* Ramnath N, 749
- Schwienhorst A. *See* Wegener D, 849
- Scoccianti S *et al.* Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience, 613
- Seitz S. *See* Szepeshazi K, 349
- Seiwert T. *See* Faoro L, 841
- Sermasappasuk P *et al.* Reduced uptake of liposomal idarubicin in the perfused rat heart, 729
- Sgro L. *See* Cavalloni G, 689
- Sharon Stack M. *See* Norton JT, 23
- Shen Z. *See* Yang X, 421
- Shih W. *See* Saraiya B, 411
- Shimizu K. *See* Kaira K, 289
- Shimizu Y. *See* Kaira K, 289
- Shin DB. *See* Park SH, 303
- Shirazi FH. *See* Dadashzadeh S, 805
- Silva KL. *See* Kwee JK, 975
- Sim E. *See* Norton JT, 23
- Singh MP. *See* Singh V, 793
- Singh SM. *See* Gupta V, 583; *also* Singh V, 793
- Singh V *et al.* Cell density-dependent alterations in tumorigenic potential of a murine T-cell lymphoma: implication in the evolution of multidrug resistance in tumor cells, 793
- Sleijfer S. *See* Mearadji A, 607
- Smirnova I. *See* Newcomb EW, 553
- Soletti RC *et al.* Potentiation of anticancer-drug cytotoxicity by sea anemone pore-forming proteins in human glioblastoma cells, 517
- Solla R. *See* Caponigro F, 739
- Son J-K. *See* Lee S, 503
- Sonabend AM *et al.* A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma, 133
- Soon-Shiong P. *See* Desai NP, 899
- Sorolla A. *See* Llobet D, 115
- Soussain C. *See* Validire P, 309
- Sova P. *See* Hrstka R, 369
- Spanjaard RA. *See* Rankin AM, 329
- Sparreboom A. *See* Chu Z, 275
- Staaf J. *See* Myhre L, 359; *also* Holst CM, 871
- Staffhorst RWHM *et al.* Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts, 721
- Stava C. *See* Fareau GG, 637
- Stemmler H-J *et al.* Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report, 832
- Strair RK. *See* Saraiya B, 411
- Strappe P. *See* Gilbert JL, 783
- Strauss H-G *et al.* Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer, 541
- Suiyu H. *See* Chunhu Z, 401
- Sun D. *See* Cui Y, 487
- Sun J *et al.* ApoG2 inhibits antiapoptotic Bcl-2 family proteins and induces mitochondria-dependent apoptosis in human lymphoma U937 cells, 967
- Sun L-R. *See* Chen M-H, 957
- Sun Q. *See* Pang L-p, 167; *also* Liu C, 825; *also* Zhong H, 1013
- Sunaga N. *See* Kaira K, 289
- Suwanjune S *et al.* Inhibition of gamma-secretase affects proliferation of leukemia and hepatoma cell lines through Notch signaling, 477
- Syrgos KN. *See* Saif MW, 447
- Szepeshazi K *et al.* Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin, 349
- Tabata M. *See* Fujiwara Y, 431
- Tai J. *See* Calabro A, 705
- Taillandier L. *See* Labussière M, 991
- Takashima S. *See* Tokudome N, 753
- Takeuchi H. *See* Nishimura R, 911
- Takigawa N. *See* Fujiwara Y, 431
- Tamaki N. *See* Nishimura R, 911
- Tan C. *See* Roforth MM, 681
- Tan S. *See* Cui Y, 487
- Tanabe S. *See* Ishido K, 921
- Tang C *et al.* Two newly synthesized 5-methyltetrahydrofolate-like compounds inhibit methionine synthase activity accompanied by cell cycle arrest in G₁/S phase and apoptosis *in vitro*, 697
- Tang S-T. *See* Tong Q-S, 573
- Tang W. *See* Chen M-H, 957
- Tang Z-Y. *See* Cui W, 891
- Tanimoto M. *See* Fujiwara Y, 431
- Tanzini G. *See* Petrioli P, 91
- ter Elst A. *See* Weidenaar AC, 45
- Terenzi H. *See* Soletti RC, 517
- Tesci A. *See* Arienti C, 983
- Thomas TP. *See* Myc A, 143
- Thomas Budd G. *See* Almhanna K, 217
- Thomssen C. *See* Strauss H-G, 541
- Thorne RF. *See* Zhang LJ, 159
- Thornton D. *See* Camidge DR, 77
- Toi M. *See* Tokudome N, 753
- Tokudome N *et al.* Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan, 753
- Tominaga T. *See* Nishimura R, 911
- Toner GC. *See* Dawson S-J, 547
- Tong Q-S *et al.* Methyl jasmonate downregulates expression of proliferating cell nuclear antigen and induces apoptosis in human neuroblastoma cell lines, 573
- Touloupidis S. *See* Giannakopoulos S, 325
- Tredici G. *See* Orciani M, 599
- Treszl A. *See* Szepeshazi K, 349
- Tretiakova M. *See* Faoro L, 841
- Tricu V. *See* Desai NP, 899
- Tsai Y-C. *See* Kao Y-H, 151
- Tsai Y-M. *See* Chen Y-J, 55
- Tuttle TM. *See* Kirstein MN, 37
- Tyler B. *See* Sonabend AM, 133
- Ueoka H. *See* Fujiwara Y, 431
- Ueyama Y. *See* Harada K, 85
- Ulasov IV. *See* Sonabend AM, 133
- Ulivi P. *See* Arienti C, 983
- Umemura S. *See* Fujiwara Y, 431
- Utsugi M. *See* Kaira K, 289
- Validire P *et al.* A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin's lymphoma patients, 309
- van Blitterswijk WJ. *See* Zerp SF, 65
- van der Born K. *See* Staffhorst RWHM, 721
- van der Luit AH. *See* Zerp SF, 65
- van Geel AN. *See* Mearadji A, 607
- Vassilopoulou-Sellin R. *See* Fareau GG, 637
- Vega-Villegas ME. *See* Rivera F, 99
- Velicu S. *See* Sonabend AM, 133
- Verheij M. *See* Zerp SF, 65
- Verhoef C. *See* Mearadji A, 607
- Vernal J. *See* Soletti RC, 517
- Verweij J. *See* Mearadji A, 607
- Villela L *et al.* Rapid complete response using intrathecal rituximab in a patient with leptomeningeal lymphomatosis due to mantle cell lymphoma, 917
- Vincent-Salomon A. *See* Decaudin D, 761
- Vink SR. *See* Zerp SF, 65

- Vojtěšek B. *See* Hrstka R, 369
- Vokes EE. *See* Faoro L, 841
- Wang D. *See* Liu C, 825; *also* Zhong H, 1013
- Wang G-S. *See* Chen Y-J, 55
- Wang H-M. *See* Chu Z, 275
- Wang J. *See* Bao H, 317
- Wang L. *See* Bao H, 317; *also* Zhang N, 593
- Wang P. *See* Zhu B-k, 189
- Wang Z. *See* Zhou H-J, 247; *also* Yang X, 421
- Ward SG. *See* Chen M-H, 957
- Watts R. *See* Zhu B-k, 189
- Wegener D *et al.* HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells, 849
- Weidenaar AC *et al.* Addition of PTK787/ZK 222584 can lower the dosage of amsacrine to achieve equal amounts of acute myeloid leukemia cell death, 45
- Weiss M. *See* Sermsappasuk P, 729
- Westerhoff M. *See* Faoro L, 841
- Wieman KM. *See* Kirstein MN, 37
- Williams BW. *See* Kirstein MN, 37
- Witschi MA. *See* Norton JT, 23
- Witt O. *See* Wegener D, 849
- Wongchana W. *See* Suwanjune S, 477
- Wu J-s. *See* Zhang H, 125
- Wu R. *See* Desai NP, 899
- Xian L-J. *See* Sun J, 967
- Xie QP. *See* Zhang LJ, 159
- Xu B. *See* Zhang N, 593; *also* Tang C, 697
- Xu W-F. *See* Chen M-H, 957
- Yamuna M. *See* Rajkumar T, 257
- Yanagita Y. *See* Nishimura R, 911
- Yanagitani N. *See* Kaira K, 289
- Yang C. *See* Dupuis C, 267
- Yang D-J. *See* Sun J, 967
- Yang J. *See* Bao H, 317
- Yang M-H. *See* Chu Z, 275
- Yang X *et al.* Biweekly docetaxel-containing chemotherapy may be the optimal schedule, 421
- Yang Y. *See* Zhong H, 1013
- Ye Y. *See* Zhang LJ, 159
- Yeramian A. *See* Llobet D, 115
- Yeruva L *et al.* Methyl jasmonate decreases membrane fluidity and induces apoptosis through tumor necrosis factor receptor 1 in breast cancer cells, 766
- Yin J. *See* Li J, 745
- Ying J-E. *See* Zhong H, 1013
- Yong D. *See* Zhong H, 1013
- Yoon DS. *See* Lim JY, 631
- Yoon S-S. *See* Park J, 777
- Yoshimura Y. *See* Harada K, 85
- Yu C-C. *See* Chen Y-J, 55
- Yu D. *See* Bao H, 317
- Yu J. *See* Ramnath N, 749
- Yunhui L. *See* Chunhu Z, 401
- Zacherl J. *See* Hejna M, 535
- Zagzag D. *See* Newcomb EW, 553
- Zak F. *See* Hrstka R, 369
- Zanni M. *See* Validire P, 309
- Zeng F-Q. *See* Tong Q-S, 573
- Zengin N. *See* Azak A, 97
- Zerp SF *et al.* Alkylphospholipids inhibit capillary-like endothelial tube formation *in vitro*: antiangiogenic properties of a new class of antitumor agents, 65
- Zhang H *et al.* Potent anticancer activity of pyrrolidine dithiocarbamate-copper complex against cisplatin-resistant neuroblastoma cells, 125
- Zhang LJ *et al.* Inhibition of apoptosis facilitates necrosis induced by cisplatin in gastric cancer cells, 159
- Zhang N *et al.* Effect of TM208 on QGY-7703 xenograft tumor growth, 593
- Zhang XD. *See* Zhang LJ, 159; *also* Zhu B-k, 189
- Zhang Y. *See* Zhong H, 1013
- Zhang Z. *See* Tang C, 697
- Zhao J *et al.* The differentiation-inducing effect of Nordy on HPV-16 subgenes-immortalized human endocervical cells H8, 713
- Zhao X. *See* Yang X, 421
- Zhao Y. *See* Zhao J, 713
- Zheng L-D. *See* Tong Q-S, 573
- Zhong B. *See* Liu C, 825; *also* Zhong H, 1013
- Zhong H *et al.* Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer, 1013
- Zhou H-J *et al.* Dihydroartemisinin induces apoptosis in human leukemia cells HL60 via downregulation of transferrin receptor expression, 247
- Zhou N-N. *See* Sun J, 967
- Zhu B-k *et al.* Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells, 189
- Zhu X. *See* Li J, 745
- Zielinski CC. *See* Hejna M, 535
- Zimmerman L. *See* Saraiya B, 411
- Zoli W. *See* Arienti C, 983
- Zuo Y. *See* Li J, 745